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Purpose: To measure vitreous, aqueous, subretinal fluid and plasma levels of vascular 
  endothelial growth factor in late stages of retinopathy of prematurity.
Methods: Interventional study. We enrolled patients with clinical diagnoses of bilateral stage 
V retinopathy of prematurity, confirmed by b-scan ultrasound and programmed for vitrectomy. 
During surgery we took samples from blood, aqueous, vitreous, and subretinal fluids. The 
vascular endothelial growth factor concentration in each sample was measured by ELISA reac-
tion. A control sample of aqueous, vitreous and blood was taken from patients with congenital 
cataract programmed for phacoemulsification. For statistical analysis, a Mann–Whitney and a 
Wilcoxon W test was done with a significant P value of 0.05.
Results: We took samples of 16 consecutive patients who met the inclusion criteria. The vas-
cular endothelial growth factor levels in the study group were: aqueous, 76.81 ± 61.89 pg/mL; 
vitreous, 118.53 ± 65.87 pg/mL; subretinal fluid, 1636.58 ± 356.47 pg/mL; and plasma, 
74.64 ± 43.94 pg/mL. There was a statistical difference between the study and the control group 
(P , 0.001) in the aqueous and vitreous samples.
Conclusion: Stage 5 retinopathy of prematurity has elevated intraocular levels of vascular 
endothelial growth factor, which remains high despite severe retinal lesion. There was no 
  statistical difference in plasma levels of the molecule between the control and study group.
Keywords: VEGF, late stages, ROP
Introduction
Retinopathy of prematurity (ROP) is an ischemia-induced vasoproliferative disease of 
multifactorial etiology.1–3 The hallmark of this pathology is the lack of development 
of normal peripheral retinal vasculature, secondary to exposure to high oxygen levels 
during the neonatal period. This leads to vascular changes, hypoxia, and overexpres-
sion of vascular endothelial growth factor (VEGF), which favors the formation of 
peripheral neovascularization, and finally retinal detachment.4,5 Despite the traditional 
role that has been given to the high levels of oxygen in the genesis of ROP, it is now 
known that there are other risk factors like low birth weight (less than 1500 g), short 
gestational age (GA) (32 weeks or less), neonatal hypoxia, hypotension, acidosis, 
neonatal sepsis, the need of mechanical ventilation, ventricular hemorrhages, the use 
of steroids after birth, blood transfusion, the presence of patent ductus arteriosus, 
apnea, and production of other molecules such as erythropoietin and other cytokines 
that could also increase the risk of presenting the disease.2,3,6–9
VEGF is a dimeric glycoprotein, normally expressed in epithelial and   neoplastic 
cells.10 Under hypoxic conditions, it is produced by pericytes, retinal pigment Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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  epithelium, and glial cells.4,10–12 Its biological activity is 
mediated by high affinity receptors (Flt-1 [VEGFR1], 
Flk-1/KDR [VEGFR2]), and it is an essential factor for retina 
angiogenesis, which under physiologic conditions results in 
the formation of the superficial and deep capillary plexus of 
the retina.5,10,13–15
The relationship between VEGF and ROP has been 
studied before.5,10,16–21 Vitreous concentrations were found 
elevated in all stages of the disease.11,22,23 However the 
opportunity to measure VEGF concentration in various ocular 
compartments at the same time is rare, since this represents, 
in most cases, an additional risk for the patient that is not 
necessarily justified. Therefore, the aim of this study is to 
measure the VEGF concentration in aqueous, vitreous, sub-
retinal fluid (SRF), and plasma of patients with stage 5 ROP, 
programmed for open-sky vitrectomy and compare them with 
a control group of healthy patients diagnosed with congenital 
cataract and programmed for phacoemulsification.
Patients and methods
The study was reviewed and approved by the hospital internal 
review board, and all procedures were performed according to 
the tenets of the Declaration of Helsinki. An informed consent 
form was obtained from all parents or legal guardians of the 
patients after a complete explanation about nature, sever-
ity, possible consequences and poor visual and anatomical 
prognosis of each particular case, and after they had received 
psychiatric counseling. The study was conducted entirely in 
our hospital facilities (level-3 ophthalmology hospital) which 
have no neonatal care. The patients included in this study 
were selected from the cases referred to our institution from 
other hospitals and private offices.
We screened patients with medical history of prematurity 
(32 weeks of gestation or less), low birth weight (2500 mg 
or less), use of supplemental oxygen after delivery and clini-
cal diagnosis of bilateral ROP stage 5, confirmed by b-scan 
ultrasound, according to the international classification of 
ROP from 1984 and 198724,25 who were programmed for 
open-sky vitrectomy. In addition, patients were classified 
into 2 groups: vascular-active ROP and vascular-inactive 
ROP in a similar manner to that made by Sonmez et al,5 
but in ROP stage 5 during surgery. The presence of retinal 
vascular changes (dilatation, tortuosity, or vitreous hemor-
rhages), as well as the persistence of neovascularization in 
the zone of traction, were the criteria for considering the case 
as active. We excluded patients with a history of previous 
treatment for ROP (laser, cryotherapy, or anti-VEGF drugs), 
surgery, and other significant systemic or ocular pathologies. 
The decision about which eye to operate on was made by the 
surgeon (HQM, GGA) depending on the appearance of the 
retinal detachment in the ultrasound at the operating room. 
All surgeries were done under general anesthesia.
For the control group, we enrolled patients with clinical 
diagnosis of congenital cataract, with no history of prematu-
rity, normal birth weight (2500–3500 mg) and no significant 
systemic or ocular pathologies, who were programmed 
for phacoemulsification with posterior capsulorhexis and 
intraocular lens implantation. An additional informed consent 
form was used for the control group.
sample collection
In the study group, undiluted aqueous, vitreous, and SRF 
samples were collected from each eye during surgery. 
Special care was taken to not contaminate the samples with 
tissue or blood during the extraction process. The aqueous 
sample was obtained with a 30GA needle by clear corneal 
paracenthesis, prior to the placement of viscoelastic and 
corneal trephination. The vitreous sample was obtained 
after lens extraction and retrolental membrane dissec-
tion by 23GA open-sky vitrectomy and manual suction. 
Finally the SRF sample was obtained by external needle 
drainage through a radial sclerotomy to avoid sample 
contamination.
The samples were then placed in eppendorf sterile tubes 
(Eppendorf AG, Hamburg, Germany) and stored at −70°C 
until analysis. The blood samples were collected by the 
anesthesiologist when gaining IV access for the anesthetic 
procedure. The sample was placed in a sterile tube with 
EDTA   (VacutainerTM, Becton Dickinson and Co, Franklin 
Lakes, NJ, USA) for immediate centrifugation at 5000 rpm 
for 5–10 minutes, until a clear separation between serum 
and the cell component was seen. The serum was then trans-
ferred into an eppendorf sterile tube and stored at −70°C 
until analysis.
In the control group, for each eye, a 2-port limbal 
phacoemulsification was used. An undiluted aqueous sample 
was collected by corneal parasenthesis with a 30GA needle 
before port construction. After lens aspiration, the anterior 
chamber was completely filled with viscoelástico mate-
rial (Amvisc® Bausch and Lomb, Rochester, NY, USA). 
A   posterior continuous curvilinear capsulorhexis was per-
formed and undiluted vitreous sample was collected during 
the anterior vitrectomy. The samples were then placed in 
eppendorf sterile tubes and stored at −70°C until assay. The Clinical Ophthalmology 2010:4
Table 1 general demographic data
No. Gender Gestational age 
(weeks at delivery)
Birth 
weight (gr)
Age at surgery  
(month)
Disease status
study group 1 M 29 1135 9 Vi
2 F 26 1040 7 VA
3 M 26 1352 10 VA
4 F 27 1441 9 Vi
5 M 27 1200 10 Vi
6 M 31 1501 12 Vi
7 M 32 1280 3 Vi
8 M 32 1370 11 VA
9 F 32 1180 11 VA
10 M 31 1205 10 VA
11 M 30 1386 8 Vi
12 M 28 1328 12 Vi
13 F 28 1090 8 VA
14 F 28 1164 6 Vi
15 M 28 1490 5 Vi
16 F 32 1235 6 VA
Control group 1 M 39 3450 63 nD
2 M 40 3200 72 nD
3 M 41 3500 84 nD
4 F 42 3650 61 nD
5 M 40 3015 76 nD
6 F 41 3260 86 nD
7 F 40 2990 49 nD
8 M 42 3430 74 nD
Notes: The gestational age and the birth weight were data extracted from the clinical history told by the parents and not from a medical record. Therefore the data may 
have some final variation.
Abbreviations: M, male; F, female; VA, vascular-active; Vi, vascular-inactive; nD, no disease.
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blood sample was taken by the anesthesiologist and processed 
in the same way as in the study group.
All samples were processed in the laboratory of the 
Department of Cellular and Molecular Neurobiology, 
  Universidad Nacional Autónoma de México, Queretaro, 
Mexico. After centrifugation at 5000 rpm for 10 minutes, 
the supernatant was discarded and an enzyme-linked 
immunosorbent assay (ELISA) reaction was made with a 
commercial kit (QuantikineTM R&D Systems Minneapolis, 
USA)   according to the manufacturer’s instructions, with a 
sensitivity of up to 9.0 pg/mL of VEGF. We used 50 µL of 
each sample for VEGF ELISA reaction. The optical density 
was determined at 450 nm, using an absorption spectro-
photometer. The mean values of 2 readings were used for 
quantitative analysis.
The statistical analysis was performed using SPSS soft-
ware, version 16.0 (Sigma Stat; Systat Software, Inc., San 
Jose, CA, USA). Data are presented as median and standard 
deviation. A Friedman/Wilcoxon W test and Mann–Whitney 
U test was used to compare VEGF concentrations between 
groups. A P value of less than 0.05 was considered to be 
statistically significant. The study was registered as a clinical 
trial (http://www.clinicaltrials.gov).
Results
We included a total of 16 consecutive patients (10 males) 
in the study group and 8 patients (5 males) in the control 
group. 7 patients (43.75%) of the study group were classi-
fied as vascular-active and 9 patients (56.25%) as vascular-
inactive. The demographic data of the study and control 
group are summarized in Table 1. The median ± standard 
deviation of the GA at delivery, in the study group was 
29.19 ± 2.23 weeks and in the control group 40.63 ± 1.06 
weeks (P , 0.001). The median birth weight of patients 
in the study group was 1274.81 ± 140.83 g and in the 
control group 3311.88 ± 235.95 g (P , 0.001). The 
median age in the study group at the moment of surgery 
was 8.56 ± 2.61 months of age and in the control group 
70.63 ± 12.40 months (P , 0.001). The ELISA results 
for VEGF of the control and study group are summarized 
in Table 2. There was a statistical difference between the 
concentrations of VEGF in aqueous and vitreous samples Clinical Ophthalmology 2010:4
Table 2 study and control group VegF results
No Aqueous  
(pg/mL)
Vitreous  
(pg/mL)
SRF  
(pg/mL)
Plasma  
(pg/mL)
study  
group
1 86.98 37.00 1326.48 98.78
2 117.36 203.25 1850.63 68.23
3 103.20 164.52 2035.54 119.42
4 138.01 175.12 1957.3 184.94
5 95.54 69.88
6 37.73 113.57 1092.08 87.55
7 49.08 215.37 1133.08 52.19
8 259.51 158.76 2057.32 42.15
9 16.50 61.4 1523.56 67.26
10 26.15 70.02 1881.00 12.46
11 65.45 205.12 1431.83 98.76
12 79.61 68.95 1658.34 130.59
13 83.54 2124.32 42.95
14 16.13 88.50 1259.30 37.59
15 16.20 42.3 1333.92 38.89
16 38.03 55.6 1883.95 41.05
Control  
group
1 12.97 12.2 44.1
2 14.52 7.8 62.8
3 16.07 5.1 28.4
4 13.36 0 42.16
5 16.46 14.7 32.61
6 18.14 8.2 45.22
7 13.25 15.1 58.38
8 16.42 11.4 51.14
Notes: The blanks in the study group correspond to samples that were discarded 
due to contamination during sampling. The control group does not have srF sample. 
Abbreviations: VEGF, vascular endothelial growth factor; SRF, subretinal fluid.
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of the study versus the control group (P , 0.005) but not 
between groups for plasma.   During the collection of sam-
ples, vitreous samples of patients 5 and 13 and SRF sample 
of patient 5 had to be discarded due to contamination with 
the patient’s blood. Finally, we regrouped the study group 
according to vascular-active or inactive status. There was 
no statistical difference in the VEGF levels of the studied 
samples (Table 3).
Discussion
The vascularization of the retina begins during the 14th week 
of gestation. This consists of 2 well recognized stages. In the 
vasculogenesis stage, precursor cells of   mesenchymal 
origins enter the retina through the optic nerve. These 
cells are responsible for the formation of the main retinal 
vessels.26 In the angiogenesis stage, the number of capil-
lary vessels increases and the peripheral retina becomes 
vascularized.27,28 In order to carry out the angiogenesis 
stage, it is necessary for the following events to occur: the 
stimulation, proliferation, and migration of endothelial cells; 
the proteolytic breakdown of the endothelial basement mem-
brane; the degradation of the adjacent extracellular matrix; 
the recruitment of support cells (pericytes); and finally the 
close of the vascular circuit.29
Growth factors are molecules with different biological 
activities. After secretion by cells they can have autocrine, 
paracrine and endocrine activity.28,29 There are several 
growth factors identified so far. Some of them have a regula-
tory role in the vascularization of the retina by stimulating 
or inhibiting the formation of vessels in either normal or 
pathological conditions.1,26,30 VEGF is a dimeric glyco-
protein overexpressed under hypoxic conditions.10–12,26 It 
directly stimulates the development of internal and external 
eye vasculature and also acts as a vascular permeability 
factor.26,29 In ROP, there is an arrest of the normal develop-
ment of peripheral retinal vascularization due to a series 
of factors that induce vascular changes. After delivery and 
after the primary insult ceases, the retinal oxygen demand 
suddenly increases. The lack of peripheral vessels pre-
vents the oxygen supply needed to meet the new demand. 
Therefore the retina enters into a state of acute hypoxia 
which favors overexpression of VEGF. In an attempt to 
counteract the deleterious effects of an excessive level of 
VEGF, the retina starts producing vasoinhibins – a group 
of molecules derived from prolactin (ie, 16 Kd-PRL) that 
inhibit angiogenesis and vascular functions.30–33   However, 
VEGF production is high enough that it easily surpasses 
the production of inhibitors. This series of events leads to 
the formation of a demarcation line between the vascular 
and avascular retina, the growth of new vessels toward the 
Table 3 Vascular-active and vascular-inactive results
Group Gestational age Aqueous VEGF 
(pg/mL)
Vitreous VEGF 
(pg/mL)
SFR VEGF  
(pg/mL)
Plasma VEGF   
(pg/mL)
Vascular-active 29.57 ± 2.82 92.04 ± 83.52 118.93 ± 64.01 1908.05 ± 199.06 56.22 ± 33.62
Vascular-inactive 28.89 ± 1.76 64.97 ± 39.88 118.24 ± 71.63 1399.04 ± 286.35 88.80 ± 47.44
Alpha value 0.66 0.53 0.94 0.09 0.2
Notes: The comparison between the results of vascular-active and vascular-inactive patients with a Friedman/Wilcoxon W test and Mann–Whitney U test did not show a 
statistical difference between these 2 groups.
Abbreviations: VEGF, vascular endothelial growth factor; SRF, subretinal fluid.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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vitreous, and finally in a tractional retinal detachment with 
severe visual impairment.5,34
The results of this study confirm the existence of 
elevated VEGF levels in vitreous, aqueous and SRF in eyes 
with stage 5 ROP, which remain high despite the significant 
damage to the intraocular structures. Although concentra-
tion in   vitreous and SRF have been studied previously, there 
is little   information about the quantities of the molecule in 
aqueous humor in this disease. VEGF is considered a key 
molecule in the regulation of angiogenesis.5 However, it is 
also found in increased amounts in other non-neovascular 
pathologies like retinal detachment and some types of 
uveitis.35,36 The high levels of VEGF in aqueous have even 
been associated with the etiology of primary open-angle 
glaucoma, pseudoexfoliation glaucoma, and neovascular 
glaucoma.37,38 Some studies have suggested that these kinds 
of glaucoma are causes of visual impairment in patients 
with advanced cases of ROP, even despite a successful 
surgical treatment.39
In the paper published by Sonmez et al, the authors mea-
sured the concentrations of VEGF in vitreous in patients with 
stage 4 ROP.5 It is remarkable that they found a statistical 
difference between the patients with a vascular-active dis-
ease and the patients considered to have a vascular-inactive 
disease.5 In our study, we tried to apply a similar approach 
to classify the patients in the study group as active or inac-
tive. However, when comparing the results between these 
2 papers, the VEGF levels in the vitreous of our active group 
were significantly lower than those reported previously by 
Sonmez (3454 versus 118.93 pg/mL). In fact, if we compare 
the combined results of our 2 groups, both vascular-active and 
vascular-inactive, the vitreous VEGF levels are more similar 
to those found in the vascular-inactive patients in the study 
by Sonmez et al (316 versus 118.53 pg/mL). This makes us 
question whether in fact what we classified as vascular-active 
disease was simply remnants of the retinal vasculature rather 
than active neovessels.
In another similar paper by Lashkari et al,10 the authors 
measured the VEGF concentration in SRF in patients with 
stage 4 and 5 ROP. Once again, our results were significantly 
lower (14770 versus 1638.58 pg/mL) despite only taking 
into account the vascular-inactive group.10 A significant 
difference between the Lashkari et al paper and ours is that 
Lashkari et al did not mention the ages of the stage 5 patients, 
which might have been the cause of the difference between 
the results. In our study group, the average age at the time of 
surgery was 8.56 ± 2.61 months. If the patients in the Lashkari 
study were younger at the time of sample collection that could 
explain the higher levels of VEGF in SRF.
There are a few limitations in this study to address. First, 
the limited number of patients in the study group makes the 
study lack sufficient statistical power to make more defini-
tive statements, and the statistical analysis available is very 
limited. A more comprehensive statistical analysis, such as a 
correlation between ROP risk factors and VEGF levels would 
have been desirable, but the fact that the control group was 
not well matched with the study group would have introduced 
a confounding factor. Despite observing significant differ-
ences in the VEGF levels of all intraocular spaces between 
the study and control groups, the information provided so far 
by our study does not allow a clear differentiation between 
in-situ VEGF production or accumulation of the molecule 
in the introacular spaces due to an increased permeability 
secondary to chronic injury. A more appropiate approach 
would have been to simultaneously measure basal levels of 
a protein that has a constant presence in plasma. If the con-
centration of this protein had also been high in the intraocular 
spaces, it would be due to an increased permeability rather 
than   in-situ   production. Finally, the control group was neither 
age nor weight matched.
In summary, ROP is a public health problem in developing 
countries and is a major cause of visual disability among chil-
dren. The ophthalmologic disorders occurring in patients after 
stage 5 ROP are not well described. The results of this study 
detect consistently high levels of VEGF in all studied fluids, 
which were statistically higher than those detected in the control 
group. However, the results were also consistently lower than 
those reported in similar series. The question of whether the 
increased VEGF level detected were due to a residual in-situ 
production or an increase in permeability of the damaged tissue 
was not answered with this study. Further studies are needed to 
complete the information obtained in this study.
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